Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

NCT04409288 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

74

Enrollment

OTHER

Sponsor class

Stopped Endpoint reached

Conditions

Prostate Cancer

Interventions

DRUG: Apalutamide
DRUG: Enzalutamide

Sponsor

Chinese University of Hong Kong

Collaborators

[object Object]